BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:7th Annual Pharma Pricing\, Reimbursement &\; Market Access 2023\n\n24th &\; 25th May 2023\, The Conference Center at Waltham Woo ds\, Waltham\, (Boston\, USA)\n\nThis conference will provide an overview of global pharma pricing\, market access systems and cost management tec hniques\, as well as in-depth discussion of some of the most current tren ds and changes. This conference will bring together top pharmaceutical\, biotechnology and regulatory representatives under one roof that will add ress the key issues of the industry. It will be studied with the help of case studies and industry experiences. Following a raft of health policy reforms impacting pharmaceutical pricing in almost every major country in the EU\, it gives me great pleasure in welcoming all of you to the Virtu e Insight’s 7th Annual Pharma Pricing\, Reimbursement &\; Market Acces s 2023.\n\nPlease contact Kavitha at E-mail - kavitha@virtueinsight.co.in  \; \; or call +44 20 3509 3779\n\nDELEGATE REGISTRATION:\n\nEARL Y BIRD (VALID TILL 27th April)\n\n1 Delegate @ $1400\n\nGroup Discount @ $2800 (3 Delegates for the price of 2)\n\nSTANDARD PRICE\n\n1 Delegate @ $1600\n\nGroup Discount @ $3200 (3 Delegates for the price of 2)\n\nSPONS ORS:\n\nRed Nucleus\n\nWe have sponsorship opportunities available for th e event\, which gives you an opportunity to speak/exhibit\, and create br and awareness. \; Here you can have a dedicated networking time\, mee t the leading international vendors and expand your knowledge of the late st business models. Please email to kavitha@virtueinsight.co.in \;&nb sp\; for more details.\n\nKEY SPEAKERS:\n\n\nDAVID BOWER\, Senior Directo r - U.S. Value &\; Access – Dermatology\, Sanofi Genzyme\nMALLORY O’CO NNOR\, Executive Director\, Public Policy\, Mallinckrodt Pharmaceuticals\ nGREG APOSTOL\, Vice President &\; Head of Market Access\, Alkermes\nB OXIONG TANG\, Executive Director\, Health Economics and\, Outcomes Resear ch (HEOR)\, BeiGene\nCHARLES BROWN\, Director\, Global Pricing and Contra cting\, Global Value &\; Access\, Novartis Gene Therapies\nRICHARD LIN ER\, Senior Assistant General Counsel\, Bayer\nSUVINA AMIN\, Director\, W orldwide HEOR\, Hematology\, Bristol-Myers Squibb\nRITU NADKARNI\, Commer cial Director\, SouthEast US\, Biogen\nLAURENE REDDING\, Global Head Stra tegic Pricing\, BeiGene\nMARGARET REHAYEM\, Vice President\, National All iance of Healthcare Purchaser Coalitions\nGARY ELLEXSON\, VP Corporate Ac counts\, Supernus Pharmaceuticals\nPETER BARSCHORFF\, Vice President\, De allus\nROBERT ROUSE\, Head of Market Access\, CSL Behring\nHEATHER LEIGH FLANNERY\, Founder &\; Chief Executive Officer\, Equideum Health\nROBE RT POPOVIAN\, VP Health Economics &\; Policy\, Equideum Health\nSEAN M ANION\, CSO\, Equideum Health\nJASON M. NOTO\, Senior VP\, US Market Acce ss\, AVEO Oncology\nSARAH EMOND\, Executive VP &\; COO\, Institute for Clinical and Economic Review (ICER)\nSCOTT HOWELL\, Former US Pharma Chi ef Strategy Officer\, Novartis\nUSMAN IQBAL\, Chief Medical Officer\, Jul z Pharma\nANGELINA IRIZARI-POLICARPIO\, Head of the U.S. HEOR &\; RWE Field Communications Team\, Eisai\nYAOZHU (JULIETTE) CHEN\, Global Eviden ce and Outcomes Lead\, Takeda\nIGOR RUDYCHEV\, VP\, Enterprise Analytics\ , Horizon Therapeutics\nALEEN HOSDAGHIAN\, Brand Lead\, US Immunology\, U CB Pharma\nLOUISE ST-ONGE\, Head of Pricing\, Market Access &\; Govern ment Affairs\, Mitsubishi Tanabe Pharma (Canada)\nRYAN CLEMENTS\, Managin g Director\, KPMG\nJOLIE APICELLA\, Partner\, Wiggin and Dana\nREED STEPH ENS\, Partner\, Winston &\; Strawn\nTED KARNEZIS\, Owner\, Karnezis Co nsulting\nNEIL PALMER\, Principal Consultant\, WN Palmer\nRUJUL DESAI\, P artner\, Covington &\; Burling\nSARA SIMON\, Attorney at Law\, Porzio Bromberg &\; Newman\n\nPlus more joining soon\n\nKEY THEMES DISCUSSED IN THIS CONFERENCE\n\n\nImplications for companies – What to Prepare for 2025?\nPharma pricing and market access in the US: From Dream to Reality\ nThe new normal: HTA &\; Reimbursement challenges in a post-pandemic w orld\nPrioritising Prioritizing patient-centred care\nThe rise of digital health and value-based healthcare\nImplementing a pricing and market acc ess strategy\nHTA and decision making in the reimbursement of medicines\n Payer’s perspective – What are they looking for?\nImportance of working t ogether - Stakeholders- Industry\, Payers\, Physicians &\; Patients\nE vidence Generation - The strategic rigor and creativity applied to eviden ce generation\nDeveloping risk-sharing reimbursement models and value-bas ed pricing\nThe international pricing system\nIntegrating real-world data into pricing\nPatient engagement and adherence within the environment\nA dding value through an innovative patient-centred approach\nRobust patien t services &\; reimbursement support program for biosimilar products\n Recent regulatory updates &\; development\n\nEnjoy and make the best o ut of our dedicated networking time\, meet the leading international vend ors showcasing the products of tomorrow in the co-located exhibition. Exp and your knowledge of the latest business models and strategies in the hi gh-level conference.\n DTEND:20230525T170000 DTSTAMP:20260512T223111Z DTSTART:20230524T090000 LOCATION:\, SEQUENCE:0 SUMMARY:7th Annual Pharma Pricing\, Reimbursement &\; Market Access 202 3\n24th &\; 25th May 2023\, The Conference Center at Waltham Woods\, W altham\, (Bost... UID:52dbaf98-a58c-4444-849e-8c599dcf1fb9 END:VEVENT END:VCALENDAR